Exclusive Summary

• - Fully off-patent globally with broad generic entry since around 2011, enabling rapid multi-market rollout
• - Large and durable patient pool as HR+ accounts for ~70% of breast cancer and endocrine therapy spans years
• - Strong guideline endorsement with unique value after non-steroidal AI failure and in combo with everolimus
• - US-FDA GMP supports entry into stringent and tender-driven markets, de-risking registration and audits
• - Generics typically deliver 80–95% savings vs originator, with highly competitive pricing in US, EU and LMIC tenders